摘要
Objective:Real-world diagnostic and treatment data for pancreatic cancer in China are lacking.As such,the present study investigated the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer(including locally advanced and metastatic disease)in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center database.Methods:A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database.The entire course of real-world pancreatic cancer management was analyzed.Results:The proportion of patients with advanced pancreatic cancer was higher among males than females(62.4%vs 37.6%,respectively).Patients typically had a history of hypertension(30.8%),diabetes(21.6%),and cholangitis(20.2%).Abdominal pain(51.6%),abdominal distension(27.1%),jaundice(20.1%),and weight loss(16.3%)were the main symptoms observed in patients with advanced pancreatic cancer in this cohort.Serum carbohydrate antigen(CA)19-9 is one of the most common tumor markers.In the present study,2562 patients underwent first-line therapy.The median progression-free survival(PFS)for patients undergoing first-line therapy was 4.1 months.The major options for first-line therapy included gemcitabine(GEM)plus S-1(GS/X)(23.4%),nab-paclitaxel plus GEM(AG)(18.1%),oxaliplatin,irinotecan,and leucovorin-modulated fluorouracil(FOLFIRINOX;11.9%),nab-paclitaxel plus S-1(AS)(8.9%),and GEM combined with oxaliplatin/cisplatin(GEMOX/GP)(7.6%).The AS and GS/X regimens were associated with the highest PFS rates.Conclusion:This is the first study to report multicenter,real-world data regarding advanced pancreatic cancer in China.Results revealed that real-world treatment options differed from guideline recommendations,and PFS was shorter than that in previously reported data.Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.
基金
funded by the National Natural Science Foundation of China(Grant nos.81874048,82171824,82272906)
Shanghai Municipal Commission of Health and Family Planning Grant 2018ZHYL0223
Shanghai Municipal Education Commission—Gao Feng Clinical Medicine Grant Support(Grant no.20161312)
Scientific and Technological Innovation Project of Science and Technology Commission of Shanghai Municipality(Grant no.21JC1404300)
Clinical Research Plan of SHDC(Grant no.SHDC2020CR1035B)
Innovation Group Project of Shanghai Municipal Health Commission(Grant no.2019CXJQ03)
National Key R&D Program of China(Grant no.2019YFC1315900)
Project from CSCO Clinical Oncology Research Foundation(Grant no.Y-2019AZZD-0513)
the Innovative Research Team of High-Level Local Universities in Shanghai(Grant no.SHSMU-ZDCX20210802).
